8-K: QuidelOrtho Reports Mixed Q4 and Full-Year 2023 Results, Cites Strong Non-Respiratory Growth

QuidelOrtho's fourth quarter and full-year 2023 results show a significant decline in respiratory revenue offset by growth in non-respiratory business and strategic investments.

Summary

• QuidelOrtho reported a revenue of $743 million for the fourth quarter of 2023, a decrease from $867 million in the same period of the previous year.
• The company's non-respiratory revenue increased by 9% in the fourth quarter, while respiratory revenue decreased by 49%.
• For the full year 2023, total revenue was $3.0 billion, down from $3.3 billion in the prior year.
• Non-respiratory revenue for the full year increased by 61%, while respiratory revenue decreased by 61%.
• The company achieved GAAP net cash from operating activities of $80 million in Q4 and $280 million for the full year.
• Adjusted free cash flow was $89 million for Q4 and $270 million for the full year.
• QuidelOrtho paid down $227 million in term loan debt and completed $7 million in share repurchases during the year.
• The company received over 700 regulatory clearances globally.
• The company is providing fiscal year 2024 financial guidance with total revenues between $2.76 and $3.07 billion.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positives like non-respiratory growth and strategic investments, the significant decline in respiratory revenue and overall financial performance compared to the previous year temper the positive aspects.

Positives

• The non-respiratory business showed strong growth, increasing by 9% in Q4 and 61% for the full year.
• The company successfully launched the Savanna molecular platform in the U.S.
• QuidelOrtho achieved significant debt reduction of $227 million.
• The company secured over 700 regulatory clearances, demonstrating global reach.
• The company is actively investing in manufacturing upgrades and its Immunohematology portfolio.
• The company is taking measures to reduce costs and improve efficiency.

Negatives

• Respiratory revenue decreased significantly, by 49% in Q4 and 61% for the full year.
• Total revenue decreased in both Q4 and the full year compared to the previous year.
• GAAP diluted EPS decreased to $0.10 in Q4 from $0.45 in the prior year period.
• GAAP diluted loss per share for the full year was $0.15, compared to diluted EPS of $9.56 in the prior year.
• GAAP operating income and margin decreased in both Q4 and the full year.
• Adjusted diluted EPS and adjusted EBITDA decreased year-over-year, primarily due to the decline in COVID-19 revenue.
• The company incurred $33 million in integration-related charges in Q4 and $113 million for the full year.

Risks

• The company faces challenges related to supply chain, production, logistics, distribution, and labor.
• There are risks associated with integrating and restructuring the combined business of Quidel and Ortho.
• The company is exposed to macroeconomic, geopolitical, market, business, competitive, and regulatory factors.
• The variability of the respiratory season and global supply chain constraints pose ongoing challenges.
• The company is winding down the U.S. Donor Screening portfolio which may impact revenue.

Future Outlook

The company is providing fiscal year 2024 financial guidance with total revenues between $2.76 and $3.07 billion, non-respiratory revenue between $2.30 and $2.34 billion, respiratory revenue between $460 and $730 million, adjusted EBITDA between $565 and $720 million, and adjusted diluted EPS between $2.40 and $3.07.

Management Comments

• In our first full year operating as a combined company, we successfully laid the foundation for building a broader-based diagnostics company poised for future growth.
• We are encouraged by the growth in our non-respiratory business, the market share gains we are seeing in our respiratory portfolios, and the U.S. launch of our Savanna molecular platform.
• We identified substantially greater synergies, while investing in the business and paying down debt.
• We have taken measures to reduce costs across the Company to lessen the impact of macro factors, such as inflation, the variability of the respiratory season and global supply chain constraints.
• We are accelerating our business efficiency initiatives, including our capital allocation strategy and portfolio management processes, to support durable long-term growth and generate shareholder value.

Industry Context

The results reflect a broader trend in the diagnostics industry where companies are experiencing a decline in COVID-19 related revenues while focusing on growth in other areas. QuidelOrtho's focus on non-respiratory business and strategic investments aligns with this trend.

Comparison to Industry Standards

• QuidelOrtho's respiratory revenue decline is consistent with the industry-wide drop in COVID-19 testing demand, similar to what companies like Abbott and Roche have reported.
• The 9% growth in non-respiratory revenue in Q4 is a positive sign, but it needs to be compared to peers like Danaher and Siemens Healthineers to assess its relative strength.
• The adjusted EBITDA margin of 26% in Q4 and 24% for the full year is lower than some industry leaders, indicating potential for improvement in operational efficiency.
• The company's focus on point-of-care diagnostics and molecular testing is in line with industry trends, but its success will depend on the adoption of its Savanna platform and other new products.
• The debt reduction of $227 million is a positive step, but the company's overall financial health needs to be evaluated against its debt-to-equity ratio and other financial metrics compared to its peers.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and profitability, but encouraged by the growth in non-respiratory business and debt reduction.
• Employees may be affected by cost reduction measures and the winding down of the U.S. Donor Screening portfolio.
• Customers will benefit from the launch of new products and the company's focus on innovation.
• Suppliers may be impacted by changes in the company's supply chain and manufacturing processes.
• Creditors will be pleased with the debt reduction.

Next Steps

• The company will hold a conference call on February 13, 2024, to discuss the financial results.
• The company will continue to focus on growing its non-respiratory business and launching new products.
• QuidelOrtho will continue to invest in its Immunohematology portfolio and wind down the U.S. Donor Screening portfolio.
• The company will accelerate business efficiency initiatives, including capital allocation strategy and portfolio management processes.

Key Dates

Keywords

in vitro diagnostics, respiratory, non-respiratory, molecular diagnostics, immunoassay, transfusion medicine, point-of-care, financial results, revenue, EBITDA, earnings, QuidelOrtho, Savanna, COVID-19